BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29339807)

  • 1. Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.
    Höti N; Yang S; Hu Y; Shah P; Haffner MC; Zhang H
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):137-146. PubMed ID: 29339807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer.
    Wang X; Chen J; Li QK; Peskoe SB; Zhang B; Choi C; Platz EA; Zhang H
    Glycobiology; 2014 Oct; 24(10):935-44. PubMed ID: 24906821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
    Liang Z; Cao J; Tian L; Shen Y; Yang X; Lin Q; Zhang R; Liu H; Du X; Shi J; Zhang J
    Cancer Lett; 2019 Dec; 467():72-84. PubMed ID: 31499120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
    Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
    Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.
    Jin R; Yamashita H; Yu X; Wang J; Franco OE; Wang Y; Hayward SW; Matusik RJ
    Oncogene; 2015 Jul; 34(28):3700-10. PubMed ID: 25220414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
    Gordon JA; Midha A; Szeitz A; Ghaffari M; Adomat HH; Guo Y; Klassen TL; Guns ES; Wasan KM; Cox ME
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):21-7. PubMed ID: 26238234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.
    Qian SB; Shen HB; Cao QF; Zhang L; Chen YF; Qi J
    Int Urol Nephrol; 2015 Mar; 47(3):479-84. PubMed ID: 25665794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
    Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
    Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
    Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
    Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
    J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
    Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
    Iguchi T; Tamada S; Kato M; Yasuda S; Machida Y; Ohmachi T; Ishii K; Iwata H; Yamamoto S; Kanamaru T; Morimoto K; Hase T; Tashiro K; Harimoto K; Deguchi T; Adachi T; Iwamoto K; Takegaki Y; Nakatani T
    Int J Clin Oncol; 2020 Mar; 25(3):486-494. PubMed ID: 31564004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian α-1,6-Fucosyltransferase (FUT8) Is the Sole Enzyme Responsible for the N-Acetylglucosaminyltransferase I-independent Core Fucosylation of High-mannose N-Glycans.
    Yang Q; Wang LX
    J Biol Chem; 2016 May; 291(21):11064-71. PubMed ID: 27008861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.